231 related articles for article (PubMed ID: 23030309)
1. Pharmacokinetic properties and bioequivalence of candesartan cilexetil in Korean healthy volunteers.
Jeon JY; Im YJ; Kim Y; Han SM; Jo MJ; Shin DH; Yoo JS; Moon BK; Kim BK; Lee BH; Choi YH; Cho BS; Jang HY; Chae SW; Kim MG
Drug Dev Ind Pharm; 2013 Sep; 39(9):1296-9. PubMed ID: 23030309
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and bioequivalence study comparing a candesartan cilexetil/rosuvastatin calcium fixed-dose combination with the concomitant administration of candesartan cilexetil and rosuvastatin calcium in healthy Korean subjects
.
Park DB; Jang K; Lee JW; Park CW; Lee BH; Kim MG; Jeon JY
Int J Clin Pharmacol Ther; 2017 Mar; 55(3):286-294. PubMed ID: 28079517
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
Hübner R; Högemann AM; Sunzel M; Riddell JG
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
[TBL] [Abstract][Full Text] [Related]
4. Bioequivalence study of two formulations of candesartan cilexetil tablet in healthy subjects under fasting conditions.
Tjandrawinata RR; Setiawati E; Yunaidi DA; Simanjuntak R; Santoso ID; Susanto LW
Drug Des Devel Ther; 2013; 7():841-7. PubMed ID: 23990709
[TBL] [Abstract][Full Text] [Related]
5. The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study.
Li KY; Liang JP; Hu BQ; Qiu Y; Luo CH; Jiang Y; Lin XP; Yang N
Clin Ther; 2010 Aug; 32(9):1674-80. PubMed ID: 20974325
[TBL] [Abstract][Full Text] [Related]
6. Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions.
Spínola AC; Almeida S; Filipe A; Neves R; Trabelsi F; Farré A
Clin Ther; 2009 Sep; 31(9):1992-2001. PubMed ID: 19843489
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic properties and bioequivalence of two irbesartan/ hydrochlorothiazide fixed-dose combination tablets in healthy male Chinese volunteers.
Liu J; Wu L; Hu X; Wu G; Zheng Y; Zhou H; Zhai Y; Zhu M; ShenTu J
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):573-81. PubMed ID: 25828636
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers.
Iqbal M; Khuroo A; Batolar LS; Tandon M; Monif T; Sharma PL
Clin Ther; 2010 Mar; 32(3):588-96. PubMed ID: 20399995
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers.
Yi S; Kim TE; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
J Cardiovasc Pharmacol; 2011 Jun; 57(6):682-9. PubMed ID: 21394036
[TBL] [Abstract][Full Text] [Related]
10. Formulation and In Vitro, In Vivo Correlation Between Two Candesartan Cilexetil Tablets.
Zaid AN; Radwan A; Jaradat N; Mousa A; Ghazal N; Bustami R
Clin Pharmacol Drug Dev; 2018 Aug; 7(6):621-626. PubMed ID: 29746726
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and Bioequivalence Studies of a Newly Developed Branded Generic of Candesartan Cilexetil Tablets in Healthy Volunteers.
Patel R; Palmer JL; Joshi S; Di Ció Gimena A; Esquivel F
Clin Pharmacol Drug Dev; 2017 Sep; 6(5):492-498. PubMed ID: 27753282
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers.
Wittayalertpanya S; Chariyavilaskul P; Prompila N; Sayankuldilok N; Eiamart W
Int J Clin Pharmacol Ther; 2014 May; 52(5):431-6. PubMed ID: 24725445
[TBL] [Abstract][Full Text] [Related]
13. No pharmacokinetic interactions between candesartan and amlodipine following multiple oral administrations in healthy subjects.
Kim JR; Kim S; Huh W; Ko JW
Drug Des Devel Ther; 2018; 12():2475-2483. PubMed ID: 30127595
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of gender difference in pharmacokinetics of Candesartan cilexetil in the fasted state by RP-HPLC: A single dose comparative study.
Nawaz HA; Masood MI; Abbas M; Usman M; Khan AM; Rasheed H; Riffat S
Pak J Pharm Sci; 2019 May; 32(3):1019-1024. PubMed ID: 31278715
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age.
Schaefer F; van de Walle J; Zurowska A; Gimpel C; van Hoeck K; Drozdz D; Montini G; Bagdasorova IV; Sorof J; Sugg J; Teng R; Hainer JW;
J Hypertens; 2010 May; 28(5):1083-90. PubMed ID: 20160654
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man.
Malerczyk C; Fuchs B; Belz GG; Roll S; Butzer R; Breithaupt-Grögler K; Herrmann V; Magin SG; Högemann A; Voith B; Mutschler E
Br J Clin Pharmacol; 1998 Jun; 45(6):567-73. PubMed ID: 9663812
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment.
de Zeeuw D; Remuzzi G; Kirch W
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S37-42. PubMed ID: 9331004
[TBL] [Abstract][Full Text] [Related]
20. Influence of hepatic dysfunction on the pharmacokinetics and safety of fimasartan.
Kim CO; Lee HW; Oh ES; Seong SJ; Kim DY; Lee J; Ahn SH; Yoon YR; Cho CM; Park MS
J Cardiovasc Pharmacol; 2013 Dec; 62(6):524-9. PubMed ID: 24084213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
